Multi-billion dollar IP dispute exposes dangers of life sciences collaborations

Seattle Genetics is demanding rights to Daiichi Sankyo’s potential blockbuster cancer treatment, which it says is an improvement on the proprietary technology included in their previous partnership


Get unlimited access to all IAM content